Clinical Trials Study
Copyright ©The Author(s) 2024.
World J Clin Cases. Aug 26, 2024; 12(24): 5523-5533
Published online Aug 26, 2024. doi: 10.12998/wjcc.v12.i24.5523
Table 1 Baseline data of patients
Parameter

A3 group
Control group
P value
SexMale22220.787
Female65
Age in yr52.14 ± 15.35258.48 ± 17.1940.155
Height in cm163.21 ± 4.756165.52 ± 7.3610.177
Weight in kg63.21 ± 7.73367.48 ± 9.9280.080
Type of strokeInfarction17170.864
Hemorrhage1110
Paretic sideRight12140.504
Left1613
HypertensionYes20210.589
No86
DiabetesYes560.686
No2321
Mean time since stroke in d49.71 ± 36.05443.63 ± 42.1640.567
MMSE27.50 ± 4.30827.19 ± 2.3540.739
BADL67.14 ± 15.83671.67 ± 10.5610.220
Brunnstrom stage3.68 ± 0.8633.89 ± 0.8010.353
SSQOL156.36 ± 23.429154.67 ± 17.2360.762
FM balance meter8.54 ± 0.9998.52 ± 0.7000.942
FMA of lower limbs20.07 ± 5.64321.22 ± 5.8200.460
RMI8.75 ± 1.9368.44 ± 1.2810.495
HWAS2.86 ± 0.7562.81 ± 0.7360.834
TUG in s32.404 ± 14.72629.643 ± 12.3480.455
Stride frequency as step/min76.018 ± 19.97886.093 ± 17.1000.050
Stride speed in cm/s45.643 ± 19.18753.389 ± 23.0090.180
Stride length in cm70.054 ± 18.92172.426 ± 24.7220.690
Lng1360.61 ± 774.6111463.70 ± 1061.3820.682
Area1889.64 ± 1334.9542165.63 ± 1474.6660.470
TL index0.901 ± 0.3610.941 ± 08830.828
Table 2 Comparison of two groups before and after intervention
OutcomeA3 group
Control group
Baseline
2 wk
Baseline
2 wk
BADL67.14 ± 15.83686.43 ± 10.874a71.67 ± 10.56175.19 ± 9.556a
SSQOL156.36 ± 23.429178.93 ± 23.650a154.67 ± 17.236158.74 ± 17.295a
FM balance meter8.54 ± 0.9999.75 ± 1.456a8.52 ± 0.7008.70 ± 0.542a
FMA (lower limbs)20.07 ± 5.64323.57 ± 5.473a21.22 ± 5.82022.19 ± 6.032a
RMI8.75 ± 1.93610.82 ± 1.679a8.44 ± 1.2818.85 ± 1.460a
HWAS2.86 ± 0.7563.75 ± 0.585a2.81 ± 0.7362.93 ± 0.675b
TUG(s)32.404 ± 14.72620.029 ± 7.228a29.643 ± 12.34826.842 ± 9.600a
Stride frequency as step/min76.018 ± 19.97894.857 ± 17.678a86.093 ± 17.10089.889 ± 13.480b
Stride speed in cm/s45.643 ± 19.18790.768 ± 77.937a53.389 ± 23.00961.796 ± 21.825a
Stride length in cm70.054 ± 18.92199.500 ± 26.606a72.426 ± 24.72281.111 ± 22.263a
Lng1360.61 ± 774.611925.36 ± 408.597a1463.70 ± 1061.3821397.04 ± 948.131b
Area1889.64 ± 1334.954980.96 ± 728.462a2165.63 ± 1474.6661755.59 ± 987.181b
TL index0.901 ± 0.3611.352 ± 0.665a0.941 ± 08830.952 ± 0.499b
Table 3 Comparison of the amount of change in clinical outcomes
Change
A3 group
Control group
P value
BADL 19.286 ± 12.1503.518 ± 4.344< 0.01
SSQOL22.571 ± 7.9884.074 ± 2.510< 0.01
FM balance meter1.214 ± 0.8320.185 ± 0.396< 0.01
FMA3.500 ± 3.8050.963 ± 2.084< 0.01
RMI2.071 ± 1.2150.407 ± 0.572< 0.01
HWAS0.893 ± 0.6290.111 ± 0.320< 0.01
TUG12.376 ± 8.9972.801 ± 3.430< 0.01
Stride frequency18.839 ± 11.2363.796 ± 10.829< 0.01
Stride speed45.125 ± 69.4098.407 ± 10.2020.009
Stride length29.446 ± 16.6248.685 ± 10.736< 0.01
Lng435.250 ± 570.53766.666 ± 517.6940.015
Area908.678 ± 972.848410.037 ± 1186.4910.094
TL index0.451 ± 0.5430.012 ± 0.7320.014